Proqr Therapeutics N.V. (PRQR) — SEC Filings
Proqr Therapeutics N.V. (PRQR) — 33 SEC filings. Latest: 6-K (May 4, 2026). Includes 29 6-K, 2 20-F, 2 SC 13G/A.
View Proqr Therapeutics N.V. on SEC EDGAR
Overview
Proqr Therapeutics N.V. (PRQR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 25, 2026: ProQR Therapeutics N.V. filed a 6-K on March 25, 2026, indicating a routine report for foreign issuers. This filing, with accession number 0001104659-26-034158, includes two documents: the 6-K form itself and an Exhibit 99.1. For investors, this specific filing doesn't contain new material financial
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 8 bullish, 25 neutral. The dominant filing sentiment for Proqr Therapeutics N.V. is neutral.
Filing Type Overview
Proqr Therapeutics N.V. (PRQR) has filed 29 6-K, 2 20-F, 2 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of PRQR's 26 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- CFO
- CMO
- Theresa Heggie
- Alison Lawton
- R.k. Beukema
- Peter van der Kuy
- Martin Maier, PhD
Top Tags
foreign-private-issuer (6) · sec-filing (3) · drug-development (3) · biotech (3) · corporate-governance (3) · 6-K (3) · shareholder-meeting (3) · rna-editing (3) · biotechnology (3) · regulatory-filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Fiscal Year End | 2024-12-31 | The period covered by the 20-F filing. |
| Filing Date | 2025-03-13 | The date ProQR Therapeutics N.V. submitted its 20-F. |
| Share Purchase Agreement Date | 2024-10-25 | Date of the agreement with Eli Lilly and Company. |
| New Funding | $8.1M | Amount secured from Rett Syndrome Research Trust to expand RNA editing programs. |
| Gross Proceeds | $100.0M | Funds raised from the public offering before expenses. |
| Shares Sold | 13.3M | Number of ordinary shares issued in the offering. |
| Price Per Share | $7.50 | The price at which each ordinary share was sold. |
| Public Document Count | 122 | Number of documents in the filing |
| SIC Code | 2834 | Standard Industrial Classification for Pharmaceutical Preparations |
Frequently Asked Questions
What are the latest SEC filings for Proqr Therapeutics N.V. (PRQR)?
Proqr Therapeutics N.V. has 33 recent SEC filings from Jan 2024 to May 2026, including 29 6-K, 2 20-F, 2 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PRQR filings?
Across 33 filings, the sentiment breakdown is: 8 bullish, 25 neutral. The dominant sentiment is neutral.
Where can I find Proqr Therapeutics N.V. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Proqr Therapeutics N.V. (PRQR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Proqr Therapeutics N.V.?
Financial highlights for Proqr Therapeutics N.V. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for PRQR?
The investment thesis for PRQR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Proqr Therapeutics N.V.?
Key executives identified across Proqr Therapeutics N.V.'s filings include CFO, CMO, Theresa Heggie, Alison Lawton, R.k. Beukema and 2 others.
What are the main risk factors for Proqr Therapeutics N.V. stock?
Of PRQR's 26 assessed filings, 0 were flagged high-risk, 9 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Proqr Therapeutics N.V.?
Forward guidance and predictions for Proqr Therapeutics N.V. are extracted from SEC filings as they are enriched.